# Zifaxaban

| | |
|---|---|
| **Cat. No.:** | HY-122592 |
| **CAS No.:** | 1378266-98-8 |
| **Molecular Formula:** | $C_{20}H_{16}ClN_3O_4S$ |
| **Molecular Weight:** | 429.88 |
| **Target:** | Factor Xa |
| **Pathway:** | Metabolic Enzyme/Protease |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |



## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an $IC_{50}$ of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research[1]. |
| **$IC_{50}$ & Target** | IC50: 11.1 nM (human FXa)[1] |
| **In Vivo** | In venous thrombosis models in rats, Zifaxaban strongly suppresses thrombus formation with $ED_{50}$ values of 3.09 mg/kg, and its best efficacy time occurred at 2 h after administration[1].<br>In arteriovenous-shunt thrombosis and carotid thrombosis models in rats, Zifaxaban inhibits thrombus formation in a dose-dependent manner[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

## REFERENCES

[1]. Qiu X, et al. Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban. Eur J Pharmacol. 2018 Oct 5;836:50-56.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA